NEWS AND MEDIA
Recent News
Purdue Pharma L.P. and the National Center for Wellness & Recovery at Oklahoma State University Announce Collaboration Around Research to Address the Opioid Addiction Crisis
Company to provide access to data and intellectual property STAMFORD, Conn./TULSA, Okla., August 15, 2019 – Purdue Pharma L.P. (“Purdue”) and the National Center for Wellness & Recovery (the “Center”) at Oklahoma State University today announced an…
Julie Ducharme, BPharm, MSc, PhD Named Vice President and Chief Scientific Officer of Purdue Pharma L.P.
STAMFORD, CT, July 2, 2019 — Purdue Pharma L.P. today announced that Julie Ducharme, BPharm, MSc, PhD will be joining the organization as Vice President and Chief Scientific Officer with accountability to help progress its existing pipeline and identify new research…
Purdue Pharma Presents Considerations in Opioid Comparator Selection at the College on Problems of Drug Dependence Annual Scientific Meeting
STAMFORD, Conn., June 18, 2019 – Purdue Pharma L.P. presented a poster describing an approach to the evaluation of opioid comparators when assessing the effectiveness of abuse-deterrent formulations (ADFs) of extended-release opioids at the College on Problems of Drug…
Purdue Pharma Announces First Participant Enrolled in Clinical Study Assessing Nalmefene HCl Injection for the Emergency Treatment of Known or Suspected Opioid Overdose
NAL1002 study will examine pharmacokinetics, safety and tolerability of nalmefene HCl Company will not profit from nalmefene HCl injection Stamford, Conn. – June 6, 2019 – Purdue Pharma L.P. today announced the initiation and first participant enrollment in a Phase 1…
Eisai and Purdue Pharma Announce Buy Out of Purdue’s Rights in Worldwide Collaboration to Develop and Commercialize Lemborexant
WOODCLIFF LAKE, N.J. and STAMFORD, Conn. – April 30, 2019 – Eisai Inc. and Purdue Pharma L.P. today announced that Eisai will buy out Purdue’s rights to the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake…
FDA Grants Competitive Generic Therapy (CGT) Designation to Purdue Pharma’s Investigational Nalmefene HCl Injection for the Emergency Treatment of Known or Suspected Opioid Overdose
Committed to advancing solutions to the opioid addiction crisis, Purdue will not profit from nalmefene HCl Stamford, Conn. – April 24, 2019 – Purdue Pharma L.P. today announced that the U.S. Food & Drug Administration (FDA)’s Office of Generic Drugs has granted…
Purdue Pharma Announces Landmark Agreement with Oklahoma to Advance the Treatment of Addiction
Settlement will establish national center for addiction studies and treatment in Tulsa; Sackler family announces voluntary contribution to support national center STAMFORD, Conn., March 26, 2019 — Purdue Pharma L.P. today announced that it has entered into a landmark…
FDA Grants Purdue Pharma’s Nalmefene HCl Injection Fast Track Designation for the Emergency Treatment of Known or Suspected Opioid Overdose
Committed to advancing solutions to the opioid public health crisis, Purdue will not profit from nalmefene HCl STAMFORD, Conn., March 13, 2019 — Purdue Pharma L.P. today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to…
Purdue Pharma Statement to 60 Minutes Regarding the Segment on Opioid Medicines Expected to Air Sunday, February 24, 2019
In 1995, the U.S. Food and Drug Administration (FDA) approved OxyContin® (oxycodone HCl) extended-release tablets CII (current Full Prescribing Information and Box Warning here)1 based on a robust set of clinical trials, which the FDA dubbed at the time the “gold…
Patients Who Receive Information About the Importance of Safe Disposal Are Three Times More Likely to Dispose of Unused Prescription Opioid Medications
Survey study sponsored by Purdue Pharma and published in the Journal of Pain Research examines factors that contribute to the safe disposal of opioids STAMFORD, Conn., February 20, 2019 — Purdue Pharma L.P. today announced the publication of a survey study that found…